144 related articles for article (PubMed ID: 28440478)
1. Overexpression of secretory phospholipase A2-IIa supports cancer stem cell phenotype via HER/ERBB-elicited signaling in lung and prostate cancer cells.
Lu S; Dong Z
Int J Oncol; 2017 Jun; 50(6):2113-2122. PubMed ID: 28440478
[TBL] [Abstract][Full Text] [Related]
2. Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells.
Dong Z; Meller J; Succop P; Wang J; Wikenheiser-Brokamp K; Starnes S; Lu S
Int J Oncol; 2014 Sep; 45(3):978-84. PubMed ID: 24913497
[TBL] [Abstract][Full Text] [Related]
3. Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer.
Oleksowicz L; Liu Y; Bracken RB; Gaitonde K; Burke B; Succop P; Levin L; Dong Z; Lu S
Prostate; 2012 Jul; 72(10):1140-9. PubMed ID: 22127954
[TBL] [Abstract][Full Text] [Related]
4. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
[TBL] [Abstract][Full Text] [Related]
5. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
6. Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer.
Dong Z; Liu Y; Scott KF; Levin L; Gaitonde K; Bracken RB; Burke B; Zhai QJ; Wang J; Oleksowicz L; Lu S
Carcinogenesis; 2010 Nov; 31(11):1948-55. PubMed ID: 20837598
[TBL] [Abstract][Full Text] [Related]
7. Vav3 oncogene is involved in regulation of secretory phospholipase A2-IIa expression in prostate cancer.
Dong Z; Liu Y; Levin L; Oleksowicz L; Wang J; Lu S
Oncol Rep; 2011 Jun; 25(6):1511-6. PubMed ID: 21455584
[TBL] [Abstract][Full Text] [Related]
8. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
9. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Kim J; Lee J; Kim C; Choi J; Kim A
Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
[TBL] [Abstract][Full Text] [Related]
10. HER2 regulates cancer stem-like cell phenotype in ALK translocated NSCLC.
Honkanen T; Wilenius E; Koivunen P; Koivunen JP
Int J Oncol; 2017 Aug; 51(2):599-606. PubMed ID: 28656214
[TBL] [Abstract][Full Text] [Related]
11. Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity.
Nakata S; Tanaka H; Ito Y; Hara M; Fujita M; Kondo E; Kanemitsu Y; Yatabe Y; Nakanishi H
Int J Oncol; 2014 Oct; 45(4):1583-93. PubMed ID: 25017791
[TBL] [Abstract][Full Text] [Related]
12. Update on HER-kinase-directed therapy in prostate cancer.
Gross ME; Jo S; Agus DB
Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
[TBL] [Abstract][Full Text] [Related]
13. Lapatinib-resistant cancer cells possessing epithelial cancer stem cell properties develop sensitivity during sphere formation by activation of the ErbB/AKT/cyclin D2 pathway.
Ohnishi Y; Yasui H; Kakudo K; Nozaki M
Oncol Rep; 2016 Nov; 36(5):3058-3064. PubMed ID: 27633099
[TBL] [Abstract][Full Text] [Related]
14. Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-kappaB signalling pathway and prognostic significance in prostate cancer.
Koumakpayi IH; Le Page C; Mes-Masson AM; Saad F
Br J Cancer; 2010 Mar; 102(7):1163-73. PubMed ID: 20216540
[TBL] [Abstract][Full Text] [Related]
15. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
16. Combined targeting of EGFR and HER2 against prostate cancer stem cells.
Rossini A; Giussani M; Ripamonti F; Aiello P; Regondi V; Balsari A; Triulzi T; Tagliabue E
Cancer Biol Ther; 2020 May; 21(5):463-475. PubMed ID: 32089070
[TBL] [Abstract][Full Text] [Related]
17. Frequent overexpression of ErbB--receptor family members in brain metastases of non-small cell lung cancer patients.
Berghoff AS; Magerle M; Ilhan-Mutlu A; Dinhof C; Widhalm G; Dieckman K; Marosi C; Wöhrer A; Hackl M; Zöchbauer-Müller S; Preusser M; Birner P
APMIS; 2013 Dec; 121(12):1144-52. PubMed ID: 23756255
[TBL] [Abstract][Full Text] [Related]
18. HER3 Is an Actionable Target in Advanced Prostate Cancer.
Gil V; Miranda S; Riisnaes R; Gurel B; D'Ambrosio M; Vasciaveo A; Crespo M; Ferreira A; Brina D; Troiani M; Sharp A; Sheehan B; Christova R; Seed G; Figueiredo I; Lambros M; Dolling D; Rekowski J; Alajati A; Clarke M; Pereira R; Flohr P; Fowler G; Boysen G; Sumanasuriya S; Bianchini D; Rescigno P; Aversa C; Tunariu N; Guo C; Paschalis A; Bertan C; Buroni L; Ning J; Carreira S; Workman P; Swain A; Califano A; Shen MM; Alimonti A; Neeb A; Welti J; Yuan W; de Bono J;
Cancer Res; 2021 Dec; 81(24):6207-6218. PubMed ID: 34753775
[TBL] [Abstract][Full Text] [Related]
19. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
[TBL] [Abstract][Full Text] [Related]
20. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
